Back to Search Start Over

Impact of CD14++ CD16+ monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study.

Authors :
Naofumi Yoshida
Hiroyuki Yamamoto
Toshiro Shinke
Hiromasa Otake
Masaru Kuroda
Daisuke Terashita
Hachidai Takahashi
Kazuhiko Sakaguchi
Yushi Hirota
Takuo Emoto
Amin, Hilman Zulkifli
Taiji Mizoguchi
Tomohiro Hayashi
Naoto Sasaki
Tomoya Yamashita
Wataru Ogawa
Ken-ichi Hirata
Source :
Cardiovascular Diabetology; 8/8/2017, Vol. 16, p1-12, 12p, 2 Diagrams, 6 Charts, 2 Graphs
Publication Year :
2017

Abstract

Background: Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14<superscript>++</superscript> CD16<superscript>+</superscript> monocytes on plaque vulnerability, as assessed by virtual histology intravascular ultrasound (VH-IVUS), as well as their relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). Methods: Fifty-one patients with asymptomatic CAD, who were undergoing lipid-lowering therapy and underwent VH-IVUS evaluation for angiographically mild to moderate lesions, were enrolled in the study. Standard VH-IVUS parameters, including the percentage volume of the necrotic core (%NC) within the plaque and the presence of a virtual histology thin-cap fibroatheroma (VH-TCFA), were then evaluated. Additionally, monocyte subsets were assessed by flow cytometry, and daily glucose fluctuations were analyzed by measuring the mean amplitude of glycemic excursion (MAGE). Results: Among 82 plaques from 22 diabetes mellitus (DM) patients and 29 non-DM patients, 15 VH-TCFAs were identified. CD14<superscript>++</superscript> CD16<superscript>+</superscript> monocyte counts significantly correlated with both %NC and the presence of VH-TCFA (%NC: r = 0.339, p = 0.002; VH-TCFA: p = 0.003). Multivariate logistic regression analysis revealed that CD14<superscript>++</superscript> CD16<superscript>+</superscript> monocyte counts were independently associated with VH-TCFA (odds ratio = 1.029, p = 0.004). Furthermore, CD14<superscript>++</superscript> CD16<superscript>+</superscript> monocyte counts were significantly correlated with the MAGE score in the non-DM patients (r = 0.544, p = 0.005). Conclusions: CD14<superscript>++</superscript>CD16<superscript>+</superscript> monocyte levels are associated with coronary plaque vulnerability and can serve as a biomarker for VH-TCFA in patients with CAD undergoing lipid-lowering therapy. In patients without DM, glucose fluctuations may alter the balance of monocyte subsets. Trial registration UMIN Registry number: UMIN000021228 [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14752840
Volume :
16
Database :
Complementary Index
Journal :
Cardiovascular Diabetology
Publication Type :
Academic Journal
Accession number :
124566421
Full Text :
https://doi.org/10.1186/s12933-017-0577-8